Human Subjects Protections in Clinical Drug Trials in China
- First Online:
- Cite this article as:
- Xu, J., Li, B., Ma, Q. et al. Int J Pharm Med (2006) 20: 367. doi:10.2165/00124363-200620060-00005
- 17 Views
With the increasing number of clinical trials being undertaken in China over the last few years, stakeholders in human subjects protections (HSP) are facing many new challenges; currently, these challenges in HSP are largely taken up by the ethical review committees and study investigators. This article identifies a number of issues with the present system and suggests ways to resolve these issues at the institutional level. Though the Chinese government has developed a basic regulatory framework for HSP, further work still needs to be done.
It is imperative that China develops a robust and reliable HSP system at the institutional level as drug studies are increasingly being undertaken in mainland China.